Business Description
Protagenic Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US74365N2027
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.2 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.53 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -7.9 | |||||
3-Year EPS without NRI Growth Rate | 2.8 | |||||
3-Year FCF Growth Rate | -19.3 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 38 | |||||
9-Day RSI | 42.08 | |||||
14-Day RSI | 44.41 | |||||
6-1 Month Momentum % | -63.65 | |||||
12-1 Month Momentum % | -69.35 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.03 | |||||
Quick Ratio | 2.03 | |||||
Cash Ratio | 1.37 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.6 | |||||
Shareholder Yield % | -2.36 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -198.14 | |||||
ROA % | -154.53 | |||||
ROIC % | -2514.13 | |||||
3-Year ROIIC % | -4937.5 | |||||
ROC (Joel Greenblatt) % | -8152.56 | |||||
ROCE % | -196.75 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 3.38 | |||||
Price-to-Tangible-Book | 3.11 | |||||
EV-to-EBIT | 0.35 | |||||
EV-to-EBITDA | 0.35 | |||||
EV-to-FCF | 0.43 | |||||
Price-to-Net-Current-Asset-Value | 3.56 | |||||
Price-to-Net-Cash | 9.96 | |||||
Earnings Yield (Greenblatt) % | 285.91 | |||||
FCF Yield % | -193.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Protagenic Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.341 | ||
Beta | 1.31 | ||
Volatility % | 106.1 | ||
14-Day RSI | 44.41 | ||
14-Day ATR (€) | 0.083665 | ||
20-Day SMA (€) | 0.6028 | ||
12-1 Month Momentum % | -69.35 | ||
52-Week Range (€) | 0.444 - 1.69 | ||
Shares Outstanding (Mil) | 4.47 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Protagenic Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Protagenic Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Protagenic Therapeutics Inc Frequently Asked Questions
What is Protagenic Therapeutics Inc(STU:MBP)'s stock price today?
When is next earnings date of Protagenic Therapeutics Inc(STU:MBP)?
Does Protagenic Therapeutics Inc(STU:MBP) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |